FDA approves LUMAKRAS in combination with Vectibix for chemorefractory KRAS G12C-mutated metastatic colorectal cancer
The U.S. Food and Drug Administration (FDA) has approved Amgen’s LUMAKRAS (sotorasib) in combination with Vectibix (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), who have received prior …